The disease burden, while showing a global decline in age-standardized incidence rates between 1990 and 2019, remains significant and continues to exhibit substantial geographic and demographic disparities, particularly in individuals aged 4064, the group with the highest incidence
Hashimotos Disease
Top-Down Approach The top-down approach used macro-level indicators: Parent market benchmarks Global/regional industry trends Economic indicators (GDP, demographics, spending patterns) Penetration and usage ratios This approach was used for segments where granular data were limited or inconsistent
Key findings Across all four trials, GLP-1 RAs were consistently associated with lower rates of alcohol-related hospitalization within one year in balanced populations: ADM trial (n = 18,515) : Alcohol-related hospitalization occurred in 10.1% of newer GLP-1 RA users vs
Muscle mass loss during GLP1 receptor agonist therapy prevented with GDF8 and activin A blockade Kokura, Yoji, et al., Science Direct (2024)